###begin article-title 0
###xml 86 94 86 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 172 177 172 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ETV6 </italic>
###xml 178 181 178 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL</italic>
###xml 187 193 187 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 194 198 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AML1</italic>
###xml 303 311 303 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 268 276 <span type="species:ncbi:9606">patients</span>
###xml 321 329 <span type="species:ncbi:9606">patients</span>
###xml 513 521 <span type="species:ncbi:9606">children</span>
The t(12;21)(p13;q22) translocation is found in 20 to 25% of cases of childhood B-lineage acute lymphoblastic leukemia (B-ALL). This rearrangement results in the fusion of ETV6 (TEL) and RUNX1 (AML1) genes and defines a relatively uniform category, although only some patients suffer very late relapse. TEL/AML1-positive patients are thus an interesting subgroup to study, and such studies should elucidate the biological processes underlying TEL/AML1 pathogenesis. We report an analysis of gene expression in 60 children with B-lineage ALL using Agilent whole genome oligo-chips (44K-G4112A) and/or real time RT-PCR.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 61 69 61 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 107 115 107 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 540 570 540 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1, TCFL5, TNFRSF7, CBFA2T3</italic>
###xml 572 575 572 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD9</italic>
###xml 577 616 577 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCARB1, TP53INP1, ACVR1C, PIK3C3, EGFL7</italic>
###xml 618 643 618 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEMA6A, CTGF, LSP1, TFPI </italic>
###xml 677 686 677 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 932 945 932 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 (AML1) </italic>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 788 795 <span type="species:ncbi:9606">patient</span>
###xml 895 902 <span type="species:ncbi:9606">patient</span>
###xml 994 1002 <span type="species:ncbi:9606">patients</span>
We compared the leukemia cell gene expression profiles of 16 TEL/AML1-positive ALL patients to those of 44 TEL/AML1-negative patients, whose blast cells did not contain any additional recurrent translocation. Microarray analyses of 26 samples allowed the identification of genes differentially expressed between the TEL/AML1-positive and negative ALL groups. Gene enrichment analysis defined five enriched GO categories: cell differentiation, cell proliferation, apoptosis, cell motility and response to wounding, associated with 14 genes -RUNX1, TCFL5, TNFRSF7, CBFA2T3, CD9, SCARB1, TP53INP1, ACVR1C, PIK3C3, EGFL7, SEMA6A, CTGF, LSP1, TFPI - highlighting the biology of the TEL/AML1 sub-group. These results were first confirmed by the analysis of an additional microarray data-set (7 patient samples) and second by real-time RT-PCR quantification and clustering using an independent set (27 patient samples). Over-expression of RUNX1 (AML1) was further investigated and in one third of the patients correlated with cytogenetic findings.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 65 73 65 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 253 261 253 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 51 59 <span type="species:ncbi:9606">children</span>
Gene expression analyses of leukemia cells from 60 children with TEL/AML1-positive and -negative B-lineage ALL led to the identification of five biological processes, associated with 14 validated genes characterizing and highlighting the biology of the TEL/AML1-positive ALL sub-group.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 759 764 759 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ETV6 </italic>
###xml 765 768 765 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL</italic>
###xml 774 780 774 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 781 785 781 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AML1</italic>
###xml 848 856 848 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 884 893 884 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 986 987 986 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 988 989 988 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1019 1027 1019 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1103 1112 1103 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 1221 1229 1221 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1340 1341 1340 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1342 1343 1342 1343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 105 113 <span type="species:ncbi:9606">children</span>
###xml 207 215 <span type="species:ncbi:9606">children</span>
###xml 870 878 <span type="species:ncbi:9606">patients</span>
###xml 1037 1045 <span type="species:ncbi:9606">patients</span>
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and is diagnosed in about 500 children in France every year [1]. Most of these malignancies (80%) involve the B lineage (B-ALL) and children have a good expected outcome on most treatment protocols. However, B-ALL is a heterogeneous disease, and therapeutically relevant standard and high-risk group categories (SR and HR) have been defined according to characteristics at diagnosis (age, white blood-cell counts, central nervous system involvement, and cytogenetic abnormalities of the leukemia cell clone). In pediatric ALL, the t(12;21)(p13;q22) chromosomal translocation is the most frequent and is found in about 25% of B-ALL cases; this translocation involves the fusion of the ETV6 (TEL) and RUNX1 (AML1) genes. Most treatment protocols result in a good outcome for TEL/AML1-positive ALL patients, but TEL/AML1 translocation is not currently used as a stratifying marker in most therapeutical protocols [2-5]. Thus, clinical features of TEL/AML1-positive patients determine whether they are in the SR or HR category. The TEL/AML1 fusion may therefore not be the single key molecular event causing leukemia spread, and if this is the case, TEL/AML1-positive ALL might involve other critical gene modifications; any such modifications remain to be documented [6,7].
###end p 9
###begin p 10
###xml 249 257 249 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 490 491 490 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 756 784 756 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2A/PBX1, BCR/ABL, TEL/AML1 </italic>
###xml 788 792 788 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 808 810 808 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 811 813 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 467 475 <span type="species:ncbi:9606">patients</span>
DNA-based microarrays can be used to study the expression levels of thousands of genes and to screen genes with different expression profiles in a single experiment. We therefore used this method to investigate the molecular pathways characterizing TEL/AML1-positive leukemia. This approach, using either one-color (Affymetrix) or two-color (NCBI) microarray technologies, has been widely used for refining the diagnosis of ALL and for predicting the response of ALL patients to treatment [8-10]. The first studies described gene expression patterns that could be used to distinguish leukemic blast lineages [11,12], and subsequent studies identified various gene expression signatures characterizing relevant clinical leukemia subtypes, in particular the E2A/PBX1, BCR/ABL, TEL/AML1 and MLL rearrangements [13-15].
###end p 10
###begin p 11
###xml 125 133 125 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 354 363 354 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1-</italic>
###xml 393 401 393 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 748 771 748 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCR/ABL, E2A/PBX1, MLL </italic>
###xml 883 892 883 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1-</italic>
###xml 911 921 911 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ETV6/RUNX1</italic>
###xml 161 169 <span type="species:ncbi:9606">patients</span>
###xml 372 380 <span type="species:ncbi:9606">patients</span>
###xml 411 419 <span type="species:ncbi:9606">patients</span>
###xml 668 676 <span type="species:ncbi:9606">patients</span>
We carried out a prospective multicentric study on childhood B-ALL leukemia to elucidate the molecular processes involved in TEL/AML1-positive leukemia. All the patients included in this study received treatment according to the French FRALLE 2000 trial. We used Agilent whole-genome oligo-chips (44K-G4112A) to compare the gene expression signatures of TEL/AML1-positive patients to those of TEL/AML1-negative patients with no recurrent chimeric products irrespective of their clinical risk category. Previous microarray gene expression studies [13-15] had revealed the effect of chromosomal alteration on transcription profiles, so we excluded from our cohort those patients with other recurrent chromosomal translocations or fusion transcripts (BCR/ABL, E2A/PBX1, MLL rearrangements). We then searched for the biological pathways associated with genes differentially expressed in TEL/AML1-positive leukemia (ETV6/RUNX1).
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient selection
###end title 13
###begin p 14
###xml 226 227 226 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 571 580 571 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 671 680 671 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 815 824 815 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 901 910 901 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 1123 1131 1123 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1203 1211 1203 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1322 1330 1322 1330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
###xml 193 201 <span type="species:ncbi:9606">patients</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 280 288 <span type="species:ncbi:9606">patients</span>
###xml 456 464 <span type="species:ncbi:9606">patients</span>
###xml 534 542 <span type="species:ncbi:9606">patients</span>
###xml 755 763 <span type="species:ncbi:9606">patients</span>
###xml 1003 1011 <span type="species:ncbi:9606">patients</span>
###xml 1089 1097 <span type="species:ncbi:9606">patients</span>
###xml 1141 1149 <span type="species:ncbi:9606">patients</span>
###xml 1221 1229 <span type="species:ncbi:9606">patients</span>
###xml 1253 1261 <span type="species:ncbi:9606">patients</span>
###xml 1343 1350 <span type="species:ncbi:9606">patient</span>
###xml 1365 1373 <span type="species:ncbi:9606">patients</span>
Sixty patients with B-lineage ALL who were treated between 2002 and 2005 according to the FRALLE 2000 protocol were included in the study. The clinical and biological characteristics of the 60 patients are summarized in Table 1. Microarray data were obtained for 33 patients; the patients were grouped into two sets (Set-A and B) according to inclusion date. Genes of interest were selected using data Set-A and tested using data Set-B. Set-A comprised 26 patients included over the three-year period up to December 2004: 19 of these patients, including six presenting a TEL/AML1 rearrangement, were in the standard-risk group (SR), and seven, including one presenting a TEL/AML1 rearrangement, belonged to the high-risk group (HR). Set-B comprised seven patients included in 2005: five, including one presenting a TEL/AML1 rearrangement, belonged to the SR group; and two, including one presenting a TEL/AML1 rearrangement, belonged to the HR group. In addition to microarray investigations with these patients, we performed Quantitative-RT-PCR with samples from an independent set of 27 patients (Set-C), including seven TEL/AML1-positive patients. None had CNS involvement. With the exception of two TEL/AML1-negative patients (SR-52 and HR-58), all patients were good early responders to treatment, and other than the TEL/AML1-negative HR patient 21, all Set-A patients were in a first complete remission phase, with a median follow-up of 46 months, at the time of the study.
###end p 14
###begin p 15
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Characteristics of the patients of the three sets (n = 60)
###end p 15
###begin p 16
WBC: white blood cell count; F:Female, M:Male
###end p 16
###begin p 17
HR and SR are respectively high risk and standard risk groups according to the FRALLE 2000 trial.
###end p 17
###begin p 18
###xml 61 62 57 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
* HR: age >/= 10 years, or white blood cell count >/= 50 x 109/l, or central nervous system involvement, or t(9;22), or t(4;11) or MLL rearrangement, or hypoploidy (</= 44 chromosomes)
###end p 18
###begin p 19
###xml 64 65 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
* SR: 1 </= age < 10 years, and white blood cell count < 50 x 109/l, and no central nervous system involvement, and none of the following cytogenetic features: t(9;22), t(4,11) or MLL rearrangement, hypoploidy
###end p 19
###begin p 20
###xml 2 10 2 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 28 36 28 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
* TEL/AML1-positive ALL and TEL/AML1-negative ALL can be assigned to HR or SR categories, according to clinical features.
###end p 20
###begin title 21
###xml 47 55 47 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
Gene expression patterns clearly distinguished TEL/AML1-positive leukemia from leukemia without recurrent chromosomal abnormalities
###end title 21
###begin p 22
###xml 62 70 62 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 94 102 94 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 513 521 513 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 554 562 554 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 677 685 677 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 767 775 767 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 898 906 898 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1100 1108 1100 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1148 1157 1148 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 1187 1195 1187 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1240 1249 1240 1249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 1353 1362 1353 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 1683 1691 1683 1691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1716 1724 1716 1724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 2118 2119 2118 2119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 2136 2145 2136 2145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 2629 2637 2629 2637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 2966 2975 2966 2975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1-</italic>
###xml 3156 3158 3156 3158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 3412 3421 3412 3421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 3486 3495 3486 3495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 3532 3541 3532 3541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 3638 3647 3638 3647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 3747 3749 3747 3749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
###xml 112 120 <span type="species:ncbi:9606">patients</span>
###xml 531 538 <span type="species:ncbi:9606">patient</span>
###xml 581 588 <span type="species:ncbi:9606">patient</span>
###xml 746 753 <span type="species:ncbi:9606">patient</span>
###xml 788 795 <span type="species:ncbi:9606">patient</span>
###xml 945 952 <span type="species:ncbi:9606">patient</span>
###xml 1087 1094 <span type="species:ncbi:9606">patient</span>
###xml 1118 1125 <span type="species:ncbi:9606">patient</span>
###xml 1173 1180 <span type="species:ncbi:9606">patient</span>
###xml 1204 1211 <span type="species:ncbi:9606">patient</span>
###xml 1376 1383 <span type="species:ncbi:9606">patient</span>
###xml 1408 1415 <span type="species:ncbi:9606">patient</span>
###xml 1548 1556 <span type="species:ncbi:9606">patients</span>
###xml 1593 1601 <span type="species:ncbi:9606">patients</span>
###xml 1773 1781 <span type="species:ncbi:9606">patients</span>
###xml 2273 2280 <span type="species:ncbi:9606">patient</span>
###xml 2653 2661 <span type="species:ncbi:9606">patients</span>
###xml 2674 2682 <span type="species:ncbi:9606">patients</span>
###xml 3501 3509 <span type="species:ncbi:9606">patients</span>
###xml 3547 3555 <span type="species:ncbi:9606">patients</span>
###xml 3660 3668 <span type="species:ncbi:9606">patients</span>
###xml 3721 3729 <span type="species:ncbi:9606">patients</span>
To identify genes with expression profiles that differentiate TEL/AML1-positive patients from TEL/AML1-negative patients with no recurrent chromosomal abnormalities we used data Set-A. We selected 10761 gene signals that displayed log-ratio intensities that were significantly different from the mean (PvalueLogRatio < 0.01) for at least one array. Only 10416 gene signals, those present on at least 70% of the Set-A arrays, were retained for SAM analysis. Two preliminary two-class SAM were performed, comparing TEL/AML1-positive patient data to either TEL/AML1-negative HR or SR patient data to assess specific sample behavior in a more homogeneous situation than the pooled TEL/AML1-negative HR and SR group [16]. Interestingly, we found that patient 18, the only TEL/AML1-positive HR patient (who was initially excluded from SAM analysis because he belonged to both groups) segregated with the TEL/AML1-positive SR group and not with the HR patient group. This is consistent with the fusion transcript affecting the gene expression profile (data not shown). Similarly, we found that patient 9, a TEL/AML1-negative patient, clustered within the TEL/AML1 branch and that patient 17, a TEL/AML1-postive patient, did not segregate into the TEL/AML1 branch. RT-PCR, using a different set of primers in a different laboratory, confirmed the presence of a TEL/AML1 transcript in patient 17 and its absence from patient 9; this indicates some heterogeneity in the TEL/AML1 group (data not shown). To avoid heterogeneity bias associated with particular patients and to highlight general processes, patients 9 and 17 were withdrawn from the two-class SAM gene-selection step comparing the TEL/AML1-positive group with the TEL/AML1-negative group. However, the data for these two patients were included in the final HC representation. To increase the robustness of gene-selection step, two cut-offs were applied successively, consistent with a 1.7-fold change, to exclude genes that varied little between the samples, (FC > 1.7), with or without a Q-value filter (Qvalue < 0.02) limiting the number of genes selected (Figure 1). This gave two TEL/AML1 gene sets, one of 181 genes and the other of 103 genes. These gene sets were used for hierarchical clustering representation of patient Set-A. Because the Set-A cohort was small, we validated our second selection (181 genes) by estimating the Benjamini and Hochberg false discovery rate (FDR): this value was consistently low (3.19% indicating only six false positives among the 181 genes designated as significant, data not shown). Both gene sets (181; 103) were able to cluster the TEL/AML1-positive Set-A patients, other than patients 9 and 17, in one branch. Hierarchical clustering highlighted 74 distinct genes among the 181 selected and they were separated into two clusters (data not shown). With the group of 103 selected genes, hierarchical clustering highlighted two clusters (44 distinct genes) able to group TEL/AML1-positive ALL (each cluster corresponds to a single branch of the hierarchical tree in which intercluster distance directly correlates with dissimilarity in gene expression) (Figure 2A). A resampling-based procedure (bootsrapping) was used to assess reproducibility (data not shown). Only these two restricted gene sets, of 74 and 44 genes, which correspond to a different profile of expression behavior associated with the presence of a TEL/AML1 chromosomal rearrangement, were able on their own to cluster the TEL/AML1 Set-A patients as previously and the TEL/AML1 Set-B patients into one branch. They were also able to segregate, with 100% reproducibility, the TEL/AML1 Set-A and -B patients together in the same branch, with the exceptions of patients 9 and 17 (Figure 2B).
###end p 22
###begin p 23
###xml 0 96 0 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Analysis flowchart: overview of the strategy used for gene selection using Set-A microarray data</bold>
###xml 245 253 245 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 271 279 271 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
Analysis flowchart: overview of the strategy used for gene selection using Set-A microarray data. At each level, the data set was filtered to remove genes that showed poor robustness and no significant difference in expression level between the TEL/AML1-positive and the TEL/AML1-negative ALL subclasses. SAM denotes Significant Analysis of Microarrays. Two groups of genes (according to the filters applied) were selected and functionally annotated. Nine of the 16 genes were selected for RT-PCR validation on the basis of their biological relevance.
###end p 23
###begin p 24
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 0 52 0 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>TEL/AML1 </italic>gene expression signature of Set-A patients</bold>
###xml 285 294 285 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 354 362 354 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 504 513 504 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 552 560 552 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1015 1023 1015 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1131 1140 1131 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 1540 1548 1540 1548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1567 1575 1567 1575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
###xml 334 342 <span type="species:ncbi:9606">patients</span>
###xml 372 380 <span type="species:ncbi:9606">patients</span>
###xml 402 409 <span type="species:ncbi:9606">patient</span>
###xml 431 438 <span type="species:ncbi:9606">patient</span>
###xml 471 478 <span type="species:ncbi:9606">patient</span>
###xml 751 759 <span type="species:ncbi:9606">Patients</span>
###xml 1149 1157 <span type="species:ncbi:9606">patients</span>
###xml 1195 1203 <span type="species:ncbi:9606">patients</span>
TEL/AML1 gene expression signature of Set-A patients. (A) Two-class SAM was applied to Set-A data. The data were filtered on the basis of a difference greater than 1.7 fold and a Q value less than 2%, leaving 103 clones (1000 permutations, median false positive = 4) associated with a TEL/AML1 signature. Clustering analysis of Set-A patients segregates TEL/AML1-positive patients together, except for patient 17 who clusters with patient 11 in a distinct branch and for patient 9 who does not present a TEL/AML1 fusion transcript, and segregates with TEL/AML1-positive ALL. Gene expression is visualized, with green and red representing down and up-regulated genes, respectively. Gray corresponds to missing data (absence of signal) as described in "Patients, Materials and Methods". The color scale above the dendrogram extends from 0.125 to 8.0 times the mean (-3 to +3 in log2 space). Two gene clusters (indicated by black arrows), consisting of either up-regulated genes or down-regulated genes, differentiate TEL/AML1-positive and -negative ALL. Gray arrows indicate the branches, which were unable on their own to segregate TEL/AML1 positive patients. (B) Support tree of Set-A and Set-B patients using the 55 clones (44 distinct genes) identified by the clustering analysis. Resampling with replacement was conducted on experiments and genes for 100 iterations. The branches of the resulted tree are colorized to denote the percentage of times a given node was supported over the resampling trials. Two branches still distinguished TEL/AML1-positive ALL from TEL/AML1-negative ALL with 100% reproducibility when Set-B samples have been added to Set-A. Two stable clusters of genes (up- and down-regulated genes) were identified and further explored by functional analysis.
###end p 24
###begin title 25
###xml 60 68 60 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
Identification of genes characterizing pathways specific to TEL/AML1-positive lymphoblasts
###end title 25
###begin p 26
###xml 49 57 49 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 102 111 102 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 558 559 558 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 678 682 678 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDK </italic>
###xml 686 691 686 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NTNG2</italic>
###xml 783 791 783 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1126 1127 1126 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1149 1180 1149 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1, CBFA2T3, TCFL5, TNFRSF7 </italic>
###xml 1216 1220 1216 1220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD9 </italic>
###xml 1336 1361 1336 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCARB1, TP53INP1, ACVR1C </italic>
###xml 1365 1372 1365 1372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIK3C3 </italic>
###xml 1432 1436 1432 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGF7</italic>
###xml 1438 1445 1438 1445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEMA6A </italic>
###xml 1449 1454 1449 1454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTGF </italic>
###xml 1501 1506 1501 1506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LSP1 </italic>
###xml 1510 1514 1510 1514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD9 </italic>
We investigated the molecular pathways depicting TEL/AML1-positive lymphoblasts by characterizing the TEL/AML1 gene sets of 74 and 44 genes identified above according to their gene ontology (GO) annotations. Five enriched GO categories were revealed: cell differentiation, cell proliferation, apoptosis, cell motility and response to wounding. Cell motility only concerned the set of 74 genes, whereas the other biological processes were obtained with both 74 and 44 gene sets. Sixteen annotated genes were associated with these biological processes (Figure 3): the literature indicates that 14 genes may be involved in B lymphoblast cell biology, but that the other two genes, MDK and NTNG2, are not. Both these genes are mainly expressed in the nervous system. Their expression in TEL/AML1-positive B-lymphoblast cells may thus be a consequence of the alteration of cell differentiation and proliferation process rather than indicating that they have a particular function in the TEL/AML1 process. Therefore, we did not include them in subsequent analyses and focused on the 14 apparently biologically relevant genes (Table 2). Over-expression of RUNX1, CBFA2T3, TCFL5, TNFRSF7 and concomitant under-expression of CD9 characterize cell proliferation and differentiation processes in the hematopoietic lineages. Over-expression of the SCARB1, TP53INP1, ACVR1C and PIK3C3 genes correlates with cell survival. Over-expression of the EGF7, SEMA6A and CTGF genes with concomitant under-expression of the LSP1 and CD9 genes is characteristic of cell migration and response to wounding.
###end p 26
###begin p 27
Genes selected for biological analysis
###end p 27
###begin p 28
###xml 74 82 74 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 100 108 100 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
The expression of all the selected genes differs by than 1.7-fold between TEL/AML1-positive ALL and TEL/AML1-negative ALL groups.
###end p 28
###begin p 29
###xml 47 56 47 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 0 89 0 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Schematic representation of selected genes for <italic>TEL/AML1 </italic>with associated enriched GO terms</bold>
###xml 176 185 176 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 223 228 <span type="species:ncbi:9606">human</span>
Schematic representation of selected genes for TEL/AML1 with associated enriched GO terms. Representation of enriched GO term analysis (p < 0.05) obtained by comparison of the TEL/AML1 gene set to the Webgestalt pre-stored human genome gene set. Each circular area represents groups of genes, sharing common properties within relevant biological processes. Five discrete enriched GO categories are identified: cell differentiation, cell proliferation, apoptosis, cell motility and response to wounding. Enriched GO categories are represented by 16 annotated genes. Six (in bold) of these 16 genes had been previously identified, and two, in brackets, were not used for further analysis because of their tissue-specific expression patterns.
###end p 29
###begin title 30
Validation of biologically relevant genes
###end title 30
###begin p 31
###xml 162 192 162 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1, TCFL5, TNFRSF7, CBFA2T3</italic>
###xml 194 197 194 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD9</italic>
###xml 199 238 199 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCARB1, TP53INP1, ACVR1C, PIK3C3, EGFL7</italic>
###xml 240 264 240 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEMA6A, CTGF, LSP1, TFPI</italic>
###xml 301 309 301 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 394 402 394 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 647 655 647 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 698 700 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 750 758 750 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 785 793 785 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 416 424 <span type="species:ncbi:9606">patients</span>
###xml 585 593 <span type="species:ncbi:9606">patients</span>
###xml 665 673 <span type="species:ncbi:9606">patients</span>
###xml 739 746 <span type="species:ncbi:9606">patient</span>
###xml 773 780 <span type="species:ncbi:9606">patient</span>
We validated the microarray results in two steps. First, we used a new microarray data set (Set-B) to perform clustering analysis based on the 14 selected genes (RUNX1, TCFL5, TNFRSF7, CBFA2T3, CD9, SCARB1, TP53INP1, ACVR1C, PIK3C3, EGFL7, SEMA6A, CTGF, LSP1, TFPI). Confirming the Set-A results, the TEL/AML1-positive ALL patients were grouped together in one branch (Figure 4A) separate from TEL/AML1-negative ALL patients, whose blast cells did not contain any recurrent chromosomal translocation. Additionally, hierarchical clustering and bootstrapping of data for Set-A and Set-B patients, using these 14 genes, satisfactorily segregated the TEL/AML1-positive patients into one branch (Figure 4B). As in the analysis described above, patient 9 (TEL/AML1-negative) and patient 17 (TEL/AML1-positive) did not classify according to their chromosomal rearrangement.
###end p 31
###begin p 32
###xml 37 46 37 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Validation of the selected genes for <italic>TEL/AML1 </italic>using Set-B microarray data</bold>
###xml 210 218 210 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 288 297 288 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 389 397 389 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 434 442 434 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 460 468 460 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 220 228 <span type="species:ncbi:9606">Patients</span>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
###xml 673 681 <span type="species:ncbi:9606">patients</span>
Validation of the selected genes for TEL/AML1 using Set-B microarray data. (A) Hierarchical clustering analyses (Euclidean distance and average linkage) of Set-B microarray data using the 14 selected genes for TEL/AML1. Patients are segregated according to the presence or absence of the TEL/AML1 rearrangement. (B) Support tree of Set-A and Set-B patients using the 14 selected genes for TEL/AML1. Two branches clearly distinguished TEL/AML1-positive ALL and TEL/AML1-negative ALL with 100% of reproducibility when resampling with replacement was conducted on experiments and genes for 100 iterations. The expression levels of the RUNX1 gene can explain the clustering of patients 9 and 17.
###end p 32
###begin p 33
###xml 113 135 113 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCFL5, PIK3C3, CBFA2T3</italic>
###xml 137 175 137 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFRSF7, RUNX1, EGFL7, TP53INP1, LSP1 </italic>
###xml 179 182 179 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD9</italic>
###xml 347 355 347 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 372 380 372 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 593 595 593 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 613 660 613 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCFL5, PIK3C3, CBFA2T3, RUNX1, EGFL7, TP53INP1 </italic>
###xml 664 672 664 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFRSF7 </italic>
###xml 696 700 696 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD9 </italic>
###xml 704 709 704 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LSP1 </italic>
###xml 732 740 732 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 770 778 770 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 931 939 931 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 311 319 <span type="species:ncbi:9606">patients</span>
###xml 884 891 <span type="species:ncbi:9606">patient</span>
###xml 949 957 <span type="species:ncbi:9606">patients</span>
Second, gene expressions were quantified using real-time RT-PCR with the independent Set-C patients. Nine genes (TCFL5, PIK3C3, CBFA2T3, TNFRSF7, RUNX1, EGFL7, TP53INP1, LSP1 and CD9) were chosen from the 14 selected above as being the most relevant biologically and able on their own to segregate Set-A and -B patients into appropriate clusters (TEL/AML1-positive versus TEL/AML1-negative; data not shown). Despite the genetic variability observed within each group (highlighted by the SD values), the mean gene expression values were significant according to Student's t-test, with either a P < 0.05 or < 0.01. TCFL5, PIK3C3, CBFA2T3, RUNX1, EGFL7, TP53INP1 and TNFRSF7 were over-expressed and CD9 and LSP1 under-expressed in the TEL/AML1-positive ALL relative to the TEL/AML1-negative subgroup, consistent with the microarray findings (Figure 5A). Hierarchical clustering of Set-C patient data using these nine genes segregated TEL/AML1-positive patients into one distinct branch (Figure 5B).
###end p 33
###begin p 34
###xml 37 46 37 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 0 105 0 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Validation of the selected genes for <italic>TEL/AML1 </italic>by quantitative RT-PCR using the independent Set-C patients</bold>
###xml 158 180 158 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCFL5, PIK3C3, CBFA2T3</italic>
###xml 182 220 182 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFRSF7, RUNX1, EGFL7, TP53INP1, LSP1 </italic>
###xml 224 228 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD9 </italic>
###xml 231 239 231 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 261 269 261 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 302 307 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LSP1 </italic>
###xml 311 315 311 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD9 </italic>
###xml 334 336 334 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 363 371 363 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 458 460 458 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 471 473 471 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 501 509 501 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 807 815 807 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 839 847 839 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 385 393 <span type="species:ncbi:9606">patients</span>
###xml 523 531 <span type="species:ncbi:9606">patients</span>
###xml 605 613 <span type="species:ncbi:9606">patients</span>
###xml 703 711 <span type="species:ncbi:9606">patients</span>
###xml 825 833 <span type="species:ncbi:9606">patients</span>
###xml 857 865 <span type="species:ncbi:9606">patients</span>
Validation of the selected genes for TEL/AML1 by quantitative RT-PCR using the independent Set-C patients. (A) Expression in log2, of mean relative levels of TCFL5, PIK3C3, CBFA2T3, TNFRSF7, RUNX1, EGFL7, TP53INP1, LSP1 and CD9 in TEL/AML1-positive (n = 7) and TEL/AML1-negative (n = 20) Set-C samples.LSP1 and CD9 are significantly (P < 0.01) under-expressed in TEL/AML1-positive ALL patients and each of the seven other genes is significantly (with either P < 0.01* or P < 0.05**) over-expressed in TEL/AML1-positive ALL patients; these findings agree with microarray data obtained with Set-A and Set-B patients. (B) Hierarchical clustering analysis (Euclidean distance and complete linkage) of Set-C patients using quantitative RT-PCR data for the nine tested genes. The dendrogram clearly distinguishes TEL/AML1-positive patients from TEL/AML1-negative patients.
###end p 34
###begin title 35
Relationship between microarray data and cytogenetic data
###end title 35
###begin p 36
###xml 50 59 50 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 60 70 60 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ETV6/RUNX1</italic>
###xml 222 231 222 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 268 281 268 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AML1 (RUNX1) </italic>
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 319 325 319 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 372 378 372 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 405 406 405 406 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 522 530 522 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 569 575 569 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 590 591 590 591 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 620 626 620 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 736 737 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 771 779 771 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 883 889 883 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 1007 1010 1007 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL</italic>
###xml 72 79 <span type="species:ncbi:9606">patient</span>
###xml 128 135 <span type="species:ncbi:9606">patient</span>
###xml 433 440 <span type="species:ncbi:9606">patient</span>
###xml 789 797 <span type="species:ncbi:9606">patients</span>
###xml 910 918 <span type="species:ncbi:9606">patients</span>
###xml 935 943 <span type="species:ncbi:9606">Patients</span>
We then examined the cytogenetic data to document TEL/AML1 (ETV6/RUNX1) patient clustering further. FISH analysis revealed that patient 9, who did not display a t(12;21) translocation but systematically clustered with the TEL/AML1 branch, presented a tetrasomy of the AML1 (RUNX1) gene (Table 3). This over-represented RUNX1 gene is consistent with the over-expression of RUNX1 seen on the microarray (log2-ratio = 0.59). Similarly, patient 17, who displayed a t(12;21) translocation and systematically clustered with the TEL/AML1-negative subgroup, had a low level of RUNX1 expression (log2-ratio = -1.31) and only two RUNX1 gene copies (FISH), even though three chromosomes 21 were detected (karyotype and chromosome painting) (Table 3). FISH analysis of the remaining TEL/AML1-positive patients (3, 5, 12, 13, 18, 23, 35, 40, 41, 43, 47, 48 and 53) revealed the presence of three RUNX1 gene copies in three patients (3, 13 and 23). Patients 3, 5, 13, 17, 18, 40 and 43 presented a deletion of the native TEL.
###end p 36
###begin p 37
###xml 42 51 42 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 52 62 52 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ETV6/RUNX1</italic>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Cytogenetic and molecular data for the 16 TEL/AML1 (ETV6/RUNX1)-positive patients
###end p 37
###begin p 38
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AML1 </italic>
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1</italic>
###xml 93 97 93 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL </italic>
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ETV6</italic>
###xml 127 132 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AML1 </italic>
FISH experiments determined AML1 (RUNX1) gene copy number and revealed whether or not native TEL (ETV6) was deleted. Increased AML1 copy number was scored when present in more than 50% of the cell population.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 14 22 14 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 208 216 208 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 249 257 249 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 428 436 428 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 885 894 885 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 986 1016 986 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1, TCFL5, TNFRSF7, CBFA2T3</italic>
###xml 1018 1021 1018 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD9</italic>
###xml 1023 1062 1023 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCARB1, TP53INP1, ACVR1C, PIK3C3, EGFL7</italic>
###xml 1064 1088 1064 1088 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEMA6A, CTGF, LSP1, TFPI</italic>
###xml 1165 1173 1165 1173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1351 1359 1351 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1684 1692 1684 1692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1709 1753 1709 1753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFRSF7, CD9, TCFL5, PIK3C3, CBFA2T3, SEMA6A</italic>
###xml 1806 1815 1806 1815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 1933 1935 1933 1935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1936 1938 1936 1938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 2123 2132 2123 2132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1-</italic>
###xml 2159 2161 2159 2161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 2234 2271 2234 2271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1, SCARB1, TP53INP1, ACVR1, EGFL7</italic>
###xml 2273 2289 2273 2289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTGF, LSP1, TFPI</italic>
###xml 2347 2353 2347 2353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TERF2 </italic>
###xml 2357 2361 2357 2361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EPOR</italic>
###xml 2583 2585 2583 2585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 2586 2588 2586 2588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 2700 2709 2700 2709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 2731 2739 2731 2739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 2743 2752 2743 2752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
###xml 485 493 <span type="species:ncbi:9606">patients</span>
###xml 535 543 <span type="species:ncbi:9606">patients</span>
###xml 1189 1197 <span type="species:ncbi:9606">patients</span>
###xml 1369 1377 <span type="species:ncbi:9606">patients</span>
###xml 1868 1876 <span type="species:ncbi:9606">patients</span>
###xml 2065 2072 <span type="species:ncbi:9606">patient</span>
###xml 2443 2450 <span type="species:ncbi:9606">patient</span>
###xml 2489 2497 <span type="species:ncbi:9606">patients</span>
The pediatric TEL/AML1-positive B-ALL subgroup displays fairly uniform clinical features, making it appropriate for studying the development of this sub-type of ALL. Comparison of gene expression profiles in TEL/AML1-positive patients with those in TEL/AML1-negative patients, whose blast cells do not contain any recurrent chromosomal rearrangement, is potentially informative about the molecular processes and pathogenesis of TEL/AML1. We first obtained microarray data for 26 B-ALL patients included in our prospective study. These patients constituted a homogeneous group, receiving an identical treatment according to the FRALLE 2000 trial. Gene expression analysis followed by gene enrichment analysis allowed us to identify five discrete enriched GO categories - cell differentiation, cell proliferation, apoptosis, cell motility and response to wounding - that highlighted the TEL/AML1 biological processes. The GO categories identified were associated with 14 annotated genes (RUNX1, TCFL5, TNFRSF7, CBFA2T3, CD9, SCARB1, TP53INP1, ACVR1C, PIK3C3, EGFL7, SEMA6A, CTGF, LSP1, TFPI); the expression patterns of these selected genes allowed clustering of the TEL/AML1-positive Set-A patients into one branch. The expression patterns of these genes, as assessed either by microarray experiments or real-time RT-PCR, were also able to cluster the TEL/AML1-positive patients of two independent sets, Set-B and -C, into one branch. Thus, even though the size of the initial set was relatively small, the filters applied were stringent enough to limit the number of false positives, leading to accuracy and subsequent validation of the 14 annotated genes. Furthermore, six of the 14 TEL/AML1-selected genes (TNFRSF7, CD9, TCFL5, PIK3C3, CBFA2T3, SEMA6A) had previously been reported to be associated with TEL/AML1 signatures found in more heterogeneous groups of ALL patients (including those with T-ALL, Bcr-Abl, E2A-PBX, or MLL) [13,15]. The identification of the same genes through different experimental approaches (Agilent, Affymetrix, NCBI) and in different patient sets is a strong argument for their importance in TEL/AML1-positive leukemia process [17], and for the relevance of the additional eight newly identified genes (RUNX1, SCARB1, TP53INP1, ACVR1, EGFL7, CTGF, LSP1, TFPI). Some genes previously described as relevant, including TERF2 and EPOR, did not appear among the genes we selected. This might be due to differences in patient sets (we did not include hyperdiploid patients, with > 50 chromosomes), or to differences in the affinities of the probe sets used [14,18]. Our findings reveal new target genes characterizing limited and specific biological pathways associated with TEL/AML1 pathogenesis. Further in vivo and in vitro investigations to assess their biological effects should contribute to a better understanding of the disease.
###end p 40
###begin p 41
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 283 291 283 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 407 429 407 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCFL5, TNFRSF7, ACVRIC</italic>
###xml 477 483 477 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 484 485 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 492 501 492 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 566 575 566 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 802 833 802 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1, CBFA2T3, PIK3CT, SCARB1 </italic>
###xml 837 846 837 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53INP1 </italic>
###xml 935 944 935 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 1053 1061 1053 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1123 1131 1123 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 1271 1273 1271 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1274 1276 1274 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
###xml 1075 1083 <span type="species:ncbi:9606">patients</span>
###xml 1145 1153 <span type="species:ncbi:9606">children</span>
Models of ALL pathogenesis have suggested that two classes of cooperating mutations are required for acute leukemia to develop [19]: one involved in impairment of differentiation and the other in cell proliferation and/or survival. We found that differentiation was not inhibited in TEL/AML1-positive ALL patients but, rather, was enhanced and characterized by the over-expression of differentiation genes (TCFL5, TNFRSF7, ACVRIC). This is in agreement with the report by Pine et al [6] that TEL/AML1 fusion preceded differentiation to pre-B cells and suggests that TEL/AML1 fusion occurs in a totipotent hematopoietic progenitor cell and directs cell differentiation towards the B-lineage. We also highlighted the activation of proliferation/survival oncogenic processes with the up-regulation of the RUNX1, CBFA2T3, PIK3CT, SCARB1 and TP53INP1 genes. Our study also implicated cell motility and response to wounding processes in the TEL/AML1 cluster. Cell migration capacity may be a clue to explaining the very late relapse events, which affect some TEL/AML1-positive ALL patients. Indeed, the good outcome expected for TEL/AML1-positive ALL children is offset by the relatively high rate of very late relapse, especially in non-hematopoietic sites such as the ovary [20,21].
###end p 41
###begin p 42
###xml 46 54 46 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL </italic>
###xml 139 143 139 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ETV6</italic>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 201 209 201 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 271 275 271 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL </italic>
###xml 369 378 369 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 436 440 436 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL </italic>
###xml 450 455 450 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AML1 </italic>
###xml 472 478 472 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 554 563 554 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1622 1628 1619 1625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 1839 1848 1836 1845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 1849 1859 1846 1856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ETV6/RUNX1</italic>
###xml 1888 1892 1885 1889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL </italic>
###xml 1920 1926 1917 1923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 1945 1951 1942 1948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 1998 2007 1995 2004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 2057 2063 2054 2060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 2165 2171 2162 2168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 2224 2230 2221 2227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 2274 2280 2271 2277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 2318 2320 2315 2317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 2350 2356 2347 2353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 2399 2405 2396 2402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 2518 2524 2515 2521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 2675 2681 2672 2678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 2734 2742 2731 2739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 2793 2799 2790 2796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 2883 2889 2880 2886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 2896 2905 2893 2902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 2926 2935 2923 2932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1-</italic>
###xml 3022 3030 3019 3027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 3092 3098 3089 3095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 3199 3205 3196 3202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 3316 3322 3313 3319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 3567 3569 3564 3566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 3570 3572 3567 3569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 3613 3622 3610 3619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 3644 3650 3641 3647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1 </italic>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
###xml 1749 1757 <span type="species:ncbi:9606">patients</span>
###xml 2007 2015 <span type="species:ncbi:9606">patients</span>
###xml 2752 2759 <span type="species:ncbi:9606">patient</span>
###xml 2779 2787 <span type="species:ncbi:9606">patients</span>
###xml 2849 2856 <span type="species:ncbi:9606">patient</span>
###xml 2944 2951 <span type="species:ncbi:9606">patient</span>
Additional genetic changes are very common in TEL/AML1-positive ALL patients; about 70% also present with deletion of the second TEL gene (ETV6) on the non-rearranged chromosome 12 [21,22]. About half TEL/AML1-positive patients (7/16) displayed an additional loss of the TEL gene, suggesting that there may be other genetic abnormalities acting as secondary events for TEL/AML1 leukemogenesis or contributing to the outcome. Unlike the TEL gene, the AML1 gene (also named RUNX1 according to the HUGO nomenclature) was significantly over-expressed in the TEL/AML1 cluster. RUNX1 is a member of the Runt transcription factor family and targets key regulators of the hematopoiesis process (M-CSF R, IL3, neutrophil elastase, MPO, granzyme B, TCRs, and B-Cell receptors) through its DNA-binding domain [23]. The transcriptional activity of RUNX1 depends on its dimerization with the non-DNA binding factor CBFbeta, and on the recruitment of co-factors. The RUNX1 transcription complex thus acts either as a transcriptional activator or as a repressor depending on the nature of the co-factors. The TEL/AML1 fusion protein (ETV6/RUNX1) associated with the t(12;21) translocation acts as a repressor. However, few of the genes selected in our analysis were down-regulated. This suggests that either gene up-regulation is an indirect process, dependent on the down-regulation of transcriptional repressors mediated by the TEL/AML1 fusion protein, or that the repressor function of the TEL/AML1 fusion protein is counterbalanced by the presence of a normal RUNX1 protein. This later possibility is supported by our observation of RUNX1 over-expression in the TEL/AML1-positive group by microarray experiments and q-PCR. Expression and cytogenetic data from patients 9 and 17 indicate that RUNX1 over-expression is not due to the expression of the TEL/AML1 (ETV6/RUNX1) fusion gene, driven by the TEL promoter, but to the native RUNX1 gene. An increased RUNX1 copy number was also found in one third of the TEL/AML1 patients, and this may explain, at least in part, RUNX1 over-expression. Gene amplification is a common mechanism of oncogene deregulation, which occurs with RUNX1 through chromosome 21 polysomy, by the presence of a RUNX1 tandem repeat on der(21) or with additional RUNX1 copies on extra-chromosomal elements [24]. The over-expression of the RUNX1 gene with no apparent amplification of the RUNX1 locus also suggests that there may be cryptic amplification undetectable by FISH-analysis or deregulation of the RUNX1 promoter. Conversely, promoter silencing or gene deletion despite over-representation of chromosome-21 could explain low expression of the RUNX1 gene. RUNX1 over-expression appeared to be characteristic of the TEL/AML1-positive patient group. Indeed, all patients with RUNX1 over-expression clustered together, including the patient 9, who had four copies of RUNX1 but no TEL/AML1 fusion. By contrast, TEL/AML1-positive patient 17, who presents no RUNX1 over-expression, did not segregate with the TEL/AML1-positive group. It is possible that the expression levels of RUNX1 could explain the clinical heterogeneity of t(12;21) ALL cases. Indeed, it has been suspected that a RUNX1 gene copy number of four is associated with ALL with good prognosis. By contrast, whereas the amplification of RUNX1 to a copy number greater than four, which has been estimated to be the case in 2% of all pediatric ALL and particularly those with no TEL/AML1 chromosomal aberration, may be characteristic of a subtype of B-ALL associated with a poor prognosis [25,26]. If these findings were confirmed, the TEL/AML1 fusion transcript and RUNX1 expression level data could be used as stratifying therapeutical markers, with possible prognostic value.
###end p 42
###begin title 43
Conclusion
###end title 43
###begin p 44
###xml 28 37 28 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 241 250 241 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 261 291 261 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX1, TCFL5, TNFRSF7, CBFA2T3</italic>
###xml 293 296 293 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD9</italic>
###xml 298 337 298 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCARB1, TP53INP1, ACVR1C, PIK3C3, EGFL7</italic>
###xml 339 363 339 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEMA6A, CTGF, LSP1, TFPI</italic>
Gene expression analysis of TEL/AML1 ALL identified five enriched gene ontology (GO) categories: cell differentiation, cell proliferation, apoptosis, cell motility and response to wounding, associated with fourteen genes able to cluster the TEL/AML1 sub-group (RUNX1, TCFL5, TNFRSF7, CBFA2T3, CD9, SCARB1, TP53INP1, ACVR1C, PIK3C3, EGFL7, SEMA6A, CTGF, LSP1, TFPI). These results, based on a small cohort, but validated by two independent data sets, should serve as a basis for a better understanding of TEL/AML1 pathogenesis and the biology of late relapse.
###end p 44
###begin title 45
Methods
###end title 45
###begin title 46
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 46
###begin p 47
###xml 402 430 402 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2A/PBX1, TEL/AML1, BCR/ABL </italic>
###xml 434 438 434 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 498 506 498 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 562 571 562 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 920 921 916 917 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 939 940 933 934 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1023 1031 1017 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 168 175 <span type="species:ncbi:9606">patient</span>
###xml 585 593 <span type="species:ncbi:9606">children</span>
Bone marrow leukemia cells were obtained at diagnosis, with informed consent, and after agreement of the Ethics Committee of Rennes Hospital (Rennes, France). For each patient, the bone marrow blast-cell level was > 80%. CD19, CD10 and CD79A were expressed in all samples and none were classified as biphenotypic ALL. Each sample was analysed by conventional karyotyping and tested for the presence of E2A/PBX1, TEL/AML1, BCR/ABL and MLL rearrangement by RT-PCR. Positive results were confirmed by in situ fluorescence analysis. Independent of the presence of a TEL/AML1 rearrangment, children were assigned to risk and treatment groups (standard risk or high risk) according to the FRALLE 2000 protocol (France Acute Lymphoblastic Leukemia de l'Enfant), with an initial risk-adapted stratification of treatment at diagnosis based on age (1 year </= age < 10 years, or >/= 10 years), white blood cell count ( < 50,000/mm3, or >/= 50,000/mm3), involvement of the central nervous system (CNS) and cytogenetic data. The early in vivo response to treatment was further assessed as the response to steroid and chemotherapy treatment, and by molecular measurement of the minimal residual disease, using polymerase chain reaction amplification on day 35 of treatment to detect the presence of clone-specific immunoglobulin and T cell receptor-gene rearrangements.
###end p 47
###begin title 48
RNA isolation, and reference RNA
###end title 48
###begin p 49
###xml 603 606 597 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
Mononuclear cells were isolated from bone marrow (2 ml samples, i.e. 5 million cells) by successive centrifugations through MLS medium (Eurobio, Courtabeuf, France). Isolated leukocytes were immediately stored at -80degreesC in 1 ml of RNA-PLUS solution (Qbiogene, Strasbourg, France). Total RNA was recovered using a Qiagen RNeasy column (Qiagen, Hilden, Germany) according to the manufacturer's instructions. In-column DNase treatment was carried out before eluting the RNA to ensure the absence of genomic DNA. Recovered RNA was quantified using a Nanodrop 1000 spectrophotometer (Nanodrop Technology(R), Cambridge, UK) and RNA integrity was assessed using a 2100 Bioanalyser (Agilent, Palo Alto, CA, USA). RNA samples with an RNA integrity number (RIN) greater than 9 were used for further analysis. We used an equimolar-pooled mixture of each test RNA sample for the reference RNA for two-color microarray technology.
###end p 49
###begin title 50
Targets preparation and microarrays hybridization
###end title 50
###begin p 51
###xml 452 461 452 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 690 694 690 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 845 853 842 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 1153 1158 <span type="species:ncbi:9606">Human</span>
RNA samples (test and reference) were labeled using the Agilent low RNA input fluorescent linear amplification Kit (p/n 5184-3523) according to the manufacturer's instructions. To avoid confounding by extraneous factors, all the experiments were performed with a single batch and processed by one technician on the same day for each step. Briefly, 500 ng of total RNA was reverse transcribed. Amplification and labeling were performed by T7-polymerase in vitro transcription, to give fluorescent-labeled cRNA. Test and reference cRNAs were labeled with Cyanine-5 and Cyanine-3 CTP dyes, respectively (10 mM, PerkinElmer, Norwalk, CT). The dye incorporation rate was assessed with a Nanodrop(R) ND-1000 spectrophotometer and was found to be between 1.2 and 1.4 pmol/mul. Hybridization was carried out using the Agilent oligonucleotide microarray in situ hybridization plus kit (p/n 5184-3568), following the manufacturer's instructions. Briefly, 750 ng of test sample cRNA was mixed with 750 ng of reference sample cRNA in the presence of target controls. This solution was subjected to fragmentation (30 min at 60degreesC) and then hybridization on 44K Human Whole-Genome 60-mer oligo-chips (G4112A, Agilent Technologies) in a rotary oven (4000 rpm, 60degreesC, 17 h). Slides were disassembled and washed in solutions I and II according to the manufacturer's instructions, and dried using a nitrogen-filled air gun before scanning.
###end p 51
###begin title 52
Data acquisition and processing
###end title 52
###begin p 53
###xml 1144 1146 1143 1145 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Microarrays were scanned with a dynamic autofocus microarray scanner (Agilent dual laser DNA microarray scanner -G2566AA, Agilent technologies, Palo Alto, CA, USA), using Agilent-provided parameters (Red and Green PMT were each set at 100%, and scan resolution was set to 10 mum). The Feature Extraction Software v7.5 (Agilent technologies, Palo Alto, CA, USA) was used to extract and analyse the signals. Agilent-provided settings were used except for subtraction of the local background and adjustment of the global background. Poor quality features that were either saturated in the two channels (50% of pixels > saturation threshold) or non-uniform were flagged. Only those features with a signal-to-noise ratio (SNR) of up to 2.6 in at least one channel and significantly different from the local background (two sided Student's t-test < 0.01) were used for further analysis. The mean signal ratio of the two fluorescent intensities (Cy-5 cRNA test /Cy-3 pooled cRNA) is expressed as a logarithm (base 2), providing a relative quantitative gene expression measurement between two samples. For subsequent analysis, we used mean-centered log2 of the normalized (linear & lowess method) sample:reference ratio.
###end p 53
###begin p 54
The accuracy of microarray results was assessed by comparing the global gene expression levels of each chip using box-plot analysis. Each box-plot was centered on zero with comparable dynamic intensities, revealing the technical homogeneity of the overall experiment (data not shown). Furthermore, technical duplicates with 25% of the Set-A cRNA samples were used to assess the reproducibility of the array.
###end p 54
###begin p 55
See additional files in microarray database "Gene Expression Omnibus" : accession number GSE 9170.
###end p 55
###begin title 56
Selection and profiling of differentially expressed genes
###end title 56
###begin p 57
Spot signals with a PvalueLogRatio < 0.01 were selected from each array and used for further analysis. Missing values, due to flagged signals, were replaced using the K-nearest neighbors calculation method with k = 10, but only when there were less than 30% of values missing per gene.
###end p 57
###begin p 58
###xml 124 132 124 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 155 163 155 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
We used two-class unpaired significance analysis of microarrays (SAM) to select genes that were differentially expressed in TEL/AML1-positive patients and TEL/AML1-negative patients [27]. Genes selected following 1000 permutations were those with expression that was more than 1.7-fold different from the mean expression. We also used a Qvalue < 0.02 as an additional discriminating parameter. Benjamini and Hochberg false discovery estimation was applied to validate our data because of the small size of the cohort. We used the agglomerative hierarchical clustering approach (average or complete linkage clustering using Euclidean distance as distance metric) in the TIGR Mev 3.1 software [28] to represent SAM-selected genes [29] and assessed reproducibility by using a resampling-based procedure (bootstrapping for 100 iterations).
###end p 58
###begin title 59
Functional annotation
###end title 59
###begin p 60
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
The genes identified by the SAM selection and hierarchical clustering representation were functionally annotated using the WebGelstalt toolkit (WEB-based GEne SeT AnaLysis Toolkit, University of Tennessee and Oak Ridge National Laboratory)[30]. WebGelstalt includes information from the Gene Ontology Tree Machine software [31] and queries were made with lists of official gene symbols (approved by the HUGO Nomenclature Committee). We retrieved enriched GO terms (i.e. GO terms with a significantly higher than expected number of associated genes) from the GOTree module (displayed as a Directed Acyclic Graph) and KEGG biochemical pathways (displayed as a KEGG table) using a hyper-geometric statistical test. Selected enriched GO terms were those that comprised at least two genes with a Pvalue < 0.05 by comparison to the pre-stored Agilent G4112A gene set. The annotation concerned only the biological process.
###end p 60
###begin title 61
Quantitative reverse transcription (RT)-PCR
###end title 61
###begin p 62
###xml 132 135 123 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 363 366 340 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 458 461 433 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 464 469 437 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABL1 </italic>
###xml 901 910 874 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
###xml 918 926 891 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1</italic>
Real-time PCR was carried out in sealed 96-well micro-titer plates using the SYBRtrade mark Green PCR Master Mix (Applied Biosystems(R)), according to Applied Biosystems gene amplification specifications (40 cycles of 15 sec at 95degreesC and 1 min at 60degreesC). We analysed gene expression using the ABI Prism 7000 sequence detection system (Applied Biosystems(R)) and evaluated the results using the associated software (version 1.2.3, Applied Biosystems(R)). ABL1 RNA was chosen as an internal positive control, because it showed no significant variation in our experiments. The relative amounts of the gene transcripts were determined using the Ct method, as described by the manufacturer. The mRNA levels are expressed with respect to the mean Ct values of all samples. Each PCR experiment was carried out in triplicate. Data are given as mean expression (with the SD) for each gene per group (TEL/AML1 and non TEL/AML1).
###end p 62
###begin p 63
###xml 142 145 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
The following forward (F) and reverse (R) primers were designed using the Primer Expresstrade mark software (version 2.0-PE Applied Biosystems(R)):
###end p 63
###begin p 64
F-ABL1: 5'-CGCTCATCACCTAAACTTGTACTTT-3';
###end p 64
###begin p 65
R-ABL1: 5'-CTGTAAGAACCGCATAAAACGA-3';
###end p 65
###begin p 66
F-CBFA2T3: 5'-TGAACTCGACATTGACGATCG-3';
###end p 66
###begin p 67
R-CBFA2T3: 5'-TCAGGAAGGGAATGACAAACG-3';
###end p 67
###begin p 68
F-CD9: 5'-CAACAAGCTGAAAACCAAGGA-3'
###end p 68
###begin p 69
R-CD9: 5'-CAAACCACAGCAGTTCAACG-3'
###end p 69
###begin p 70
F-EGFL7: 5'-TTGCCAGTCAGATGTGGATGA-3'
###end p 70
###begin p 71
R-EGFL7: 5'-ACTCTGTGTGCCCAAGGGAG-3'
###end p 71
###begin p 72
F-LSP1: 5'-AGGGGGAGCAAGAGGACA-3'
###end p 72
###begin p 73
R-LSP1: 5'-CCCCTCCTTGCTCAGACTC-3'
###end p 73
###begin p 74
F-PIK3C3: 5'-GCCTTGGAACTTCTGGGAAAA-3';
###end p 74
###begin p 75
R-PIK3C3: 5'-CAACAGCATAACGCCTCACAG-3';
###end p 75
###begin p 76
F-RUNX1: 5'-ACAAACCCACCGCAAGTC-3'
###end p 76
###begin p 77
R-RUNX1: 5'-catctagtttctgccgatgtctt-3'
###end p 77
###begin p 78
F-TCFL5: 5'-GCGCAGAATCCGCATTTG-3';
###end p 78
###begin p 79
R-TCFL5: 5'-TCAGGAATGCTGTGGTCCACT-3'
###end p 79
###begin p 80
F-TNFRSF7: 5'-AGGGACAAGGAGTGCACCG-3';
###end p 80
###begin p 81
R-TNFRSF7: 5'-AAGGTAAGTGGGTGGGCTGAG-3';
###end p 81
###begin p 82
F-TP53INP1: 5'-GCATGTCTGTCTATGCTGTGC-3'
###end p 82
###begin p 83
R-TP53INP1: 5'-TTCATTTTGAGCTTCCACTCTG-3'
###end p 83
###begin p 84
Primer specificity was assessed from their mono-phase dissociation curves and all pairs presented comparable efficiencies (data not shown).
###end p 84
###begin title 85
Karyotype and FISH analysis
###end title 85
###begin p 86
###xml 188 193 <span type="species:ncbi:9606">human</span>
At the time of the diagnosis, chromosome analyses were performed on bone marrow samples using a RHG-banding technique. Karyotypes were designated according to the International System for human Cytogenetic Nomenclature (ISCN, 1995).
###end p 86
###begin p 87
###xml 13 21 13 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 187 196 187 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEL/AML1 </italic>
Fluorescence in situ hybridization (FISH) analyses were performed when a t(12;21) was suspected (either RT-PCR or karyotype), according to the manufacturer's protocol using the Vysis LSI TEL/AML1 bicolor probe (Abbott, Rungis, France).
###end p 87
###begin title 88
Authors' contributions
###end title 88
###begin p 89
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 568 576 <span type="species:ncbi:9606">patients</span>
###xml 652 660 <span type="species:ncbi:9606">patients</span>
###xml 806 814 <span type="species:ncbi:9606">patients</span>
VG interpreted and analyzed the data, drafted of the article, made critical revisions, a substantial intellectual contribution, provided study materials/patients, and collected and assembled the data. AGR provided major contribution concerning biological and process information and analyzed the data. MDT contributed to the statistical analysis of the data, making a major intellectual contribution. VS contributed to data acquisition and processing, interpreted and analyzed the data. SM and AM interpreted and analyzed the data. BLS and CH provided study materials/patients, and collected and assembled the data. CS and ELG provided study materials/patients and critical revisions. ALT provided platform support and critical revisions. CB interpreted and analyzed the data, and provided study materials/patients. JYLG and JM contributed to the concept and design of the study, provided critical revisions and made major intellectual contributions. MDG contributed to the concept and design of the study, interpreted and analyzed the data, contributed critical revisions and intellectual input, gave final approval, and collected and assembled the data.
###end p 89
###begin title 90
Competing interests
###end title 90
###begin p 91
The author(s) declares that there are no competing interests.
###end p 91
###begin title 92
Acknowledgements
###end title 92
###begin p 93
###xml 200 208 <span type="species:ncbi:9606">children</span>
We thank members of the CNRS-UMR6061 Genetics and Development unit for helpful discussions and comments. We are grateful to Drs. B. Bruno and C. Habay from the department of Oncopediatrics and to the children and parents who agreed to participate in the study. We are indebted to D. Gillet in Brest and Dr. F. Fouyssac in Nancy for data monitoring, to Dr. V. Hugo for sample storage, to R. Bouvier for help with real-time PCR analysis and to Dr. F. Lemee (Rennes), Dr. B. Leotard (Nancy) and Prof. M. De Braekeleer (Brest) for their valuable assistance with cytogenetic analysis.
###end p 93
###begin p 94
This work was supported by the Delegation a la Recherche Clinique du CHU de Rennes (a publicly funded research agency), the Ligue contre le Cancer foundation, the Region Bretagne and the CNRS.
###end p 94
###begin article-title 95
Survival in France after childhood acute leukaemia and non-Hodgkin's lymphoma (1990-2000)
###end article-title 95
###begin article-title 96
Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia
###end article-title 96
###begin article-title 97
Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia
###end article-title 97
###begin article-title 98
Expression of TEL-AML1 fusion transcripts and response to induction therapy in standard risk acute lymphoblastic leukemia
###end article-title 98
###begin article-title 99
###xml 181 189 <span type="species:ncbi:9606">Children</span>
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)
###end article-title 99
###begin article-title 100
TEL-AML1 fusion precedes differentiation to pre-B cells in childhood acute lymphoblastic leukemia
###end article-title 100
###begin article-title 101
###xml 104 112 <span type="species:ncbi:9606">children</span>
Mechanism, detection and clinical significance of the reciprocal translocation t(12;21)(p12;q22) in the children suffering from acute lymphoblastic leukaemia
###end article-title 101
###begin article-title 102
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
###end article-title 102
###begin article-title 103
Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia
###end article-title 103
###begin article-title 104
Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia
###end article-title 104
###begin article-title 105
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring
###end article-title 105
###begin article-title 106
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Identification of gene expression profiles that segregate patients with childhood leukemia
###end article-title 106
###begin article-title 107
Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia
###end article-title 107
###begin article-title 108
Classification of pediatric acute lymphoblastic leukemia by gene expression profiling
###end article-title 108
###begin article-title 109
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling
###end article-title 109
###begin article-title 110
Prognostic signature of ALL blasts at diagnosis: What can we really find?
###end article-title 110
###begin article-title 111
Inter-platform comparability of microarrays in acute lymphoblastic leukemia
###end article-title 111
###begin article-title 112
###xml 76 84 <span type="species:ncbi:9606">children</span>
Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia
###end article-title 112
###begin article-title 113
Focus on acute leukemias
###end article-title 113
###begin article-title 114
Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes
###end article-title 114
###begin article-title 115
Late ovarian relapse of TEL/AML1 positive ALL confirming that TEL deletion is a secondary event in leukemogenesis
###end article-title 115
###begin article-title 116
Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome
###end article-title 116
###begin article-title 117
Role of AML1/Runx1 in the pathogenesis of hematological malignancies
###end article-title 117
###begin article-title 118
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Genetic abnormalities associated with the t(12;21) and their impact in the outcome of 56 patients with B-precursor acute lymphoblastic leukemia
###end article-title 118
###begin article-title 119
Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome
###end article-title 119
###begin article-title 120
###xml 69 77 <span type="species:ncbi:9606">children</span>
Amplification of band q22 of chromosome 21, including AML1, in older children with acute lymphoblastic leukemia: an emerging molecular cytogenetic subgroup
###end article-title 120
###begin article-title 121
Significance analysis of microarrays applied to the ionizing radiation response
###end article-title 121
###begin article-title 122
TIGR Mev 3.1 [www.tigr.org/software/tm4]
###end article-title 122
###begin article-title 123
TM4: a free, open-source system for microarray data management and analysis
###end article-title 123
###begin article-title 124
WebGelstat toolkit [genereg.ornl.gov/webgestalt]
###end article-title 124
###begin article-title 125
GOTree Machine (GOTM): a web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies
###end article-title 125

